Advancing Quantification of Diffusion MRI for Oncologic Imaging

 描述(由申请人提供)：本次更新继续努力建立弥散加权磁共振成像(DWI)作为癌症患者的定量成像指标。根据我们迄今的进展，这项更新工作将通过三个具体目标以及NCI定量成像网络(QIN)、IMBIO、LLC(工业合作伙伴)和国家标准与技术研究所(NIST)内的战略合作来推进。(目标1)将通过建立直方图和基于体素的指标来开发用于扩散分析的标准化平台，并验证用于量化肿瘤扩散值的DWI指标。(目标2)与NIST合作，使用原位测温技术开发新一代DWI体模，在整个临床相关的ADC范围内进行精确的扩散测量，以在不同的扫描仪平台上产生定量的质量保证和系统性能指标。(目的3)基于测量的系统特性，在多中心试验中实现DW非线性误差的回溯校正是可能的。这项研究工作将解决建立用于治疗反应评估的弥散加权成像的主要障碍，以改善癌症患者的临床管理。我们将开发并严格测试一个医学成像平台，以便标准化实施和临床验证先进的DWI分析技术，以量化跨多个MRI系统的肿瘤扩散值。我们还将继续我们广泛采用的冰水DWI体模的成功，开发下一代DWI体模平台，该平台将提供整个组织范围内扩散值的定量扩散测量。最后，我们将提供一种策略，通过开发特定于系统的校正工具，解决磁共振成像梯度系统中与仪器偏差相关的DWI技术变异性的一个主要来源。我们QIN项目的续签将为临床试验提供先进的分析和质量保证支持，包括I-SPY2(通过成像和分子分析预测您的治疗反应的系列研究的调查)、ACRIN 6698和ACRIN 6702。这一努力的成功将极大地促进癌症患者的临床管理，最终改善结果。

 DESCRIPTION (provided by applicant): This renewal continues efforts toward establishing diffusion-weighted MRI (DWI) as a quantitative imaging metric for cancer patients. Based upon our progress to date, this renewal effort will be advanced through three Specific Aims along with strategic collaborations within the NCI Quantitative Imaging Network (QIN), Imbio, LLC (industrial partner) and the National Institute of Standards and Technology (NIST). (Aim 1) Development of a standardized platform for diffusion analysis and validation of DWI metrics for quantification of tumor diffusion values will be accomplished through establishment of histogram and voxel-based metrics. (Aim 2) In collaboration with NIST, development of the next generation DWI phantom using in-situ thermometry for precise diffusion measurements over the full clinically-relevant ADC range to generate quantitative quality assurance and system performance metrics across diverse scanner platforms. (Aim 3) Based on measured system characteristics, implementation of retrospective correction of DW nonlinearity errors in multi-center trials is possible. This research effort will address major hurdles in establishing DWI for therapeutic response assessment to improve clinical management of cancer patients. We will develop and rigorously test a medical imaging platform allowing for a standardized implementation and clinical validation of advanced DWI analytical techniques for quantification of tumor diffusion values across multiple MRI systems. We will also continue the success of our widely-adopted ice water DWI phantom with the development of a next-generation DWI phantom platform that will provide quantitative diffusion measurements over the full tissue range of diffusion values. Finally, we will provide a strategy for resolving a major source of technical variability in DWI related to instrumental bias from differences in MRI gradient systems through the development of system-specific correction tools. The renewal of our QIN project will provide advanced analytical and quality assurance support to clinical trials including I-SPY2 (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis, ACRIN 6698, and ACRIN 6702. Success of this endeavor will significantly advance the clinical management of cancer patients ultimately improving outcomes.